Macrogen Launches Special Promotion on Exome Sequencing to Celebrate Their 20th Anniversary
Macrogen Inc. (CEO Hyon-yong Chong, www.macrogen.com) (KOSDAQ:038290), a precision medicine biotechnology company, announced on June 1st that it is launching a special promotion on Exome Sequencing to celebrate their 20th anniversary.
During this special promotion period, Macrogen will offer Exome Sequencing service with 100x coverage using SureSelect Human All Exon V5 (50M) or V6 (58M) capture kit at a special price of $299 per sample. This is an innovative price that has never been offered anywhere else before. Through this promotion, researchers around the world can take advantage of Macrogen’s Exome service that is known for its high-quality data and fast Turnaround Time (TAT) on very special price terms.
Macrogen has obtained the highest level of genome analysis technology in the world through continuous technological development and research activities for the past 20 years. In 2016, Macrogen established the world's highest-precision reference of a Korean genome (Nature, 2016) and has since been recognized globally for its outstanding academic capacity and technology. Furthermore, in order to strengthen its position as the technological leader, Macrogen purchased the latest sequencing equipment, NovaSeq6000 (Illumina Inc.). This enables Macrogen to analyze over 70,000 human genomes, or 8,000Tb per year.
Macrogen’s CEO Hyon-yong Chong said, "This Exome promotion is not only to celebrate the 20th anniversary of Macrogen, but is also to satisfy our customers with its competitive edge in low price and top-notch analytical service." Chong added, "Macrogen will always strive to provide services that our customers can value."
For further details on this promotion, please refer to below link:
http://dna.macrogen.com/eng/support/event/event_view.jsp?board_number=26475
For
details on service and ordering, please contact ngs@macrogen.com.
About Macrogen
Macrogen is a leading service provider of integrated genomic research dedicated to providing the highest quality genomics services. Macrogen provide a wide range of sequencing and bioinformatics services to the academic, pharmaceutical, and clinical research communities around the world. For more information on Macrogen, please visit www.macrogen.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170602005035/en/
Contact information
Macrogen Inc.
Elena J Kim, +82-2-2113-7355
NGS overseas sales
& marketing division
ngs@macrogen.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Intelsat, Cubic³ Complete Vehicle Satellite Connectivity Test, Advancing Ubiquitous Connectivity Vision14.5.2025 10:00:00 EEST | Press release
Intelsat and Cubic³ have successfully completed a critical vehicle satellite connectivity test, marking a significant milestone in their joint mission to create a seamless connectivity service for all types of vehicles. The test demonstrated successful integration between Intelsat satellites and Cubic³’s software platform, showcasing how terrestrial and non-terrestrial networks can seamlessly link to deliver always-on connectivity regardless of location. “Our Memorandum of Understanding and successful test brings us closer to our vision of truly ubiquitous connectivity,” said Bruno Fromont, Intelsat Chief Technology Officer. “By combining Intelsat’s satellite expertise with Cubic³’s innovative connectivity platform, we’re creating solutions that will keep vehicles connected anywhere in the world, enabling critical functions from broadband connectivity, diagnostics to eventually supporting autonomous driving capabilities.” The successful test focused on a commercial land mobile use case
Norli Liv & Pension Modernizes Investment Operations with Clearwater Analytics14.5.2025 10:00:00 EEST | Press release
Clearwater Analytics (NYSE: CWAN), the most comprehensive technology platform for investment management, today announced that Danish pension provider, Norli Liv & Pension, part of the Norli group, has partnered with Clearwater to modernize its investment accounting, reporting and compliance operations. Clearwater will provide Norli with a single, consolidated view of all in-house and outsourced chief investment officer (OCIO) managed holdings across its public and private asset classes—enhancing investment transparency and empowering better, faster decision-making. The platform will also support regulatory compliance through automated workflows and robust, audit-ready reporting. By moving to Clearwater’s single instance, multi-tenant platform, Norli Liv & Pension will eliminate multiple legacy platforms, reduce manual work and accelerate its monthly close. The platform’s “single pane of glass” view will provide users across departments with unified access to accurate, timely data and a
GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD)14.5.2025 09:14:00 EEST | Press release
GSK plc (LSE/NYSE: GSK) and Boston Pharmaceuticals, a leading clinical stage biopharmaceutical company developing highly targeted therapies for patients with serious liver diseases, today announced that they have entered into an agreement under which GSK will acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa. Efimosfermin is a phase III-ready, potential best-in-class, investigational specialty medicine to treat and prevent progression of steatotic liver disease (SLD). Under the agreement, GSK will pay $1.2 billion upfront, with potential for additional success-based milestone payments totalling $800 million. Efimosfermin is a novel, once-monthly fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), including cirrhosis, and future development in alcohol-related liver disease (ALD), both forms of SLD. Given efimosfermin’s direct antifibrotic mechanism of action and GSK’s dat
Reply Presents “App to the Future”: A New AI-Scape Room Experience Powered by Microsoft AI and Low-Code Solutions14.5.2025 09:05:00 EEST | Press release
Reply, a global systems integrator and technology consulting firm, introduces “App to the Future” an immersive “AI-Scape Room” an immersive escape room experience powered by Microsoft Copilot, Azure AI, and Power Platform, designed to explore the full potential of AI and low-code tools in a unique and engaging way. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250513072546/en/ The experience builds on Reply’s AI-Scape Room focused on Microsoft 365 Copilot, offering enhanced challenges and deeper integration of advanced AI tools to help participants better understand how these technologies can drive business transformation. Developed by WM Reply and Valorem Reply, the Reply companies specialised in digital workplace transformation and AI solutions, “App to the Future” invites participants to engage in an interactive experience where they tackle AI-powered challenges using Microsoft’s suite of tools - including Copilot, Azure
Svante Launches World's First Commercial Gigafactory for Carbon Capture & Removal Filters13.5.2025 23:50:00 EEST | Press release
Svante Technologies Inc. (Svante), a global leader in carbon capture and removal technologies, has officially completed the commissioning of its new Centre of Excellence for Carbon Capture and Removal – Redwood manufacturing Facility (Redwood) in Burnaby, British Columbia. This milestone marks the launch of the world's first gigafactory dedicated to producing commercial-scale carbon capture and removal filters designed to trap CO2 directly from industrial emissions and the atmosphere, and with the mindset of high-volume automation and product standardization to lower the manufacturing cost. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250513713072/en/ Claude Letourneau, President & CEO, Svante Group opens the Svante Grand Opening 2025 event, "GO25" with a speech about how to move the carbon management industry forward. This two-day event celebrates the commissioning of Svante's gigafactory in Vancouver, BC, Canada, which w
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom